| ChemoCentryx Presents Data on CCX168, an Orally Administered Small Molecule ... - GlobeNewsWire (press release) |
|
|
GlobeNewsWire (press release) CCX168 is currently in a multinational, randomized, double-blind, placebo-controlled Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis, an inflammation of small blood vessels in the |